MA40031A - Nucléosides substitués, nucléotides et analogues de ceux-ci - Google Patents

Nucléosides substitués, nucléotides et analogues de ceux-ci

Info

Publication number
MA40031A
MA40031A MA040031A MA40031A MA40031A MA 40031 A MA40031 A MA 40031A MA 040031 A MA040031 A MA 040031A MA 40031 A MA40031 A MA 40031A MA 40031 A MA40031 A MA 40031A
Authority
MA
Morocco
Prior art keywords
analogs
nucleotides
substituted nucleosides
nucleosides
nucleotide analogs
Prior art date
Application number
MA040031A
Other languages
English (en)
Inventor
Leonid Beigelman
Lawrence M Blatt
Natalia Dyatkina
David Bernard Smith
Julian Alexander Symons
Original Assignee
Alios Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc filed Critical Alios Biopharma Inc
Publication of MA40031A publication Critical patent/MA40031A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des nucléosides, des analogues de nucléotides, des procédés de synthèse d'analogues de nucléotides et des procédés de traitement de maladies et/ou d'états pathologiques, tels qu'une infection virale par les filoviridae, avec un ou plusieurs nucléosides et/ou analogues de nucléotides.
MA040031A 2014-06-24 2015-06-22 Nucléosides substitués, nucléotides et analogues de ceux-ci MA40031A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462016219P 2014-06-24 2014-06-24
US201462034629P 2014-08-07 2014-08-07
US201462061819P 2014-10-09 2014-10-09

Publications (1)

Publication Number Publication Date
MA40031A true MA40031A (fr) 2015-12-30

Family

ID=54868667

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040031A MA40031A (fr) 2014-06-24 2015-06-22 Nucléosides substitués, nucléotides et analogues de ceux-ci

Country Status (17)

Country Link
US (4) US9603863B2 (fr)
EP (1) EP3160475B1 (fr)
JP (1) JP6669675B2 (fr)
CN (1) CN106604734B (fr)
AP (1) AP2016009653A0 (fr)
AU (1) AU2015280234B2 (fr)
CA (1) CA2952959C (fr)
EA (1) EA201692537A1 (fr)
IL (1) IL249627A0 (fr)
MA (1) MA40031A (fr)
MX (1) MX2016017381A (fr)
NZ (1) NZ727582A (fr)
PH (1) PH12016502563A1 (fr)
SG (1) SG11201610597QA (fr)
TN (1) TN2016000566A1 (fr)
TW (1) TW201613613A (fr)
WO (1) WO2015200205A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
CA2908313A1 (fr) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Traitement contre une infection par le virus de l'hepatite c utilisant une combinaison de composes
MX2015017556A (es) 2013-06-26 2016-05-09 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015054465A1 (fr) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Nucléosides substitués, nucléotides substitués et analogues de ceux-ci
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
AU2015320511B2 (en) 2014-09-26 2020-11-12 Riboscience Llc 4'-vinyl substituted nucleoside derivatives as inhibitors of Respiratory Syncytial Virus RNA replication
US20170246209A1 (en) * 2014-10-06 2017-08-31 Nantkwest, Inc. Treating viral hemorrhagic fever with nk-92 cells
WO2016069489A1 (fr) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Procédés de préparation d'analogues de nucléosides substitués
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
CA3182565A1 (fr) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. Nucleotides de purine ?-d-2'-desoxy-2'?-fluoro-2'-?-c-substitues-2-modifies-n6-substitues pour le traitement du virus de l'hepatite c
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
EA201892448A1 (ru) * 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018048937A1 (fr) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. Nucléotides de purine substitués en position 2'-n 6 pour le traitement du virus à arn
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
CA3059777C (fr) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Formes cristallines de (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphor yl)amino)propanoate
WO2019014247A1 (fr) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprenant un inhibiteur d'arn polymérase et de la cyclodextrine pour le traitement d'infections virales
CA3075950A1 (fr) * 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Nucleosides substitues, nucleotides et analogues de ceux-ci
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
KR20200140274A (ko) * 2018-03-07 2020-12-15 에모리 유니버시티 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도
EP3773753A4 (fr) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. Traitement de patients infectés par le virus de l'hépatite c avec une cirrhose
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权（第2 号）有限公司 用于hiv治疗的化合物
MA55556A (fr) * 2019-04-02 2022-02-09 Aligos Therapeutics Inc Composés ciblant prmt5
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
WO2021188959A1 (fr) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Promédicaments de nucléosides de 4'-c-substitué-2-halo-2'-désoxyadénosine et leurs procédés de fabrication et d'utilisation
CA3172483A1 (fr) 2020-04-06 2021-10-14 Scott Ellis Formulations d'inhalation d'analogues de carbanucleosides a substitution 1'-cyano
AR121836A1 (es) * 2020-04-14 2022-07-13 Janssen Sciences Ireland Unlimited Co Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
CA3216162A1 (fr) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Procedes de preparation de carbanucleosides a l'aide d'amides
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
CN113735929A (zh) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 一种抗冠状病毒的化合物及其制备方法与应用
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN116554249B (zh) * 2022-01-28 2025-03-18 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease
US20250282812A1 (en) * 2022-04-20 2025-09-11 Shanghai Institute Of Materia Medica , Chinese Academy Of Sciences Antiviral nucleoside analogue, and pharmaceutical composition and use thereof
CN115322170B (zh) * 2022-08-29 2023-06-02 苏州华一新能源科技股份有限公司 一种硫酸乙烯酯的制备方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN116589510B (zh) * 2023-04-20 2025-08-26 安徽大学 一种氟代苄基核糖中间体的制备方法与应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
WO2002069903A2 (fr) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, leur preparation et utilisation en tant qu'inhibiteurs de polymerases virales d'arn
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
WO2006033709A2 (fr) 2004-07-29 2006-03-30 Metabasis Therapeutics, Inc. Nouveaux derives de nucleosides
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US20090176732A1 (en) 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
US8475804B2 (en) * 2009-02-20 2013-07-02 U.S. Army Medical Research And Material Command Compositions and methods for treatment of filovirus-mediated diseases
JP2012521359A (ja) * 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
WO2010108135A1 (fr) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Analogues nucleotidiques protégés
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
EP2619215B1 (fr) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucléosides et analogues nucléotidiques
WO2012040126A1 (fr) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Analogues de nucléotides substitués
CA2819041A1 (fr) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Analogues de nucleotides cycliques
AU2012357940B2 (en) 2011-12-20 2017-02-16 Riboscience Llc 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
WO2013142159A1 (fr) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8846896B2 (en) 2012-03-21 2014-09-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
GEP201706721B (en) * 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2013142157A1 (fr) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
EP2935304A1 (fr) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
WO2014134251A1 (fr) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Compositions pharmaceutiques
WO2014164533A1 (fr) 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Méthodes de synthèse stéréosélective d'analogues nucléosidiques substitués
CA2908313A1 (fr) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Traitement contre une infection par le virus de l'hepatite c utilisant une combinaison de composes
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2015017556A (es) 2013-06-26 2016-05-09 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
LT3043803T (lt) * 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
WO2015054465A1 (fr) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Nucléosides substitués, nucléotides substitués et analogues de ceux-ci
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
AU2015280245A1 (en) 2014-06-24 2017-01-05 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
CA2955604A1 (fr) 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methodes de traitement de paramyxovirus
PE20170673A1 (es) 2014-08-05 2017-05-22 Alios Biopharma Inc Terapia de combinacion para tratar una paramixovirus
WO2016069489A1 (fr) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Procédés de préparation d'analogues de nucléosides substitués
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
TW201811339A (zh) 2016-08-12 2018-04-01 美商艾洛斯生物製藥公司 經取代之核苷、核苷酸及其類似物
US20180117042A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
CA3075950A1 (fr) 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Nucleosides substitues, nucleotides et analogues de ceux-ci

Also Published As

Publication number Publication date
WO2015200205A1 (fr) 2015-12-30
EP3160475A4 (fr) 2018-02-21
EA201692537A1 (ru) 2017-05-31
JP2017519780A (ja) 2017-07-20
CN106604734A (zh) 2017-04-26
EP3160475A1 (fr) 2017-05-03
JP6669675B2 (ja) 2020-03-18
US20150366887A1 (en) 2015-12-24
EP3160475C0 (fr) 2024-01-03
US20190054108A1 (en) 2019-02-21
AP2016009653A0 (en) 2016-12-31
US9603863B2 (en) 2017-03-28
IL249627A0 (en) 2017-02-28
CA2952959A1 (fr) 2015-12-30
US10780105B2 (en) 2020-09-22
CN106604734B (zh) 2021-08-13
AU2015280234A1 (en) 2017-01-12
SG11201610597QA (en) 2017-01-27
US10052342B2 (en) 2018-08-21
US20210106604A1 (en) 2021-04-15
AU2015280234B2 (en) 2021-04-01
US20170143751A1 (en) 2017-05-25
CA2952959C (fr) 2023-03-07
PH12016502563A1 (en) 2017-04-17
NZ727582A (en) 2018-06-29
EP3160475B1 (fr) 2024-01-03
MX2016017381A (es) 2017-08-14
TN2016000566A1 (en) 2018-04-04
TW201613613A (en) 2016-04-16
US11590155B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
PH12016502563A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12016502564A1 (en) Substituted nucleosides, nucleosides and analogs thereof
MX2017008183A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
PH12016500660A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12020551055A1 (en) Methods for treating filoviridae virus infections
WO2018031818A3 (fr) Nucléosides substitués, nucléotides et analogues de ceux-ci
PH12015502799A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
HK1243714A1 (zh) 制备取代的核苷类似物的方法
HK1216535A1 (zh) 取代的核苷、核苷酸及其類似物
HK1224229A1 (zh) 取代的核苷，核苷酸及其类似物
LT3265102T (lt) Beta-d-2'-deoksi-2'alfa-fluor-2'-beta-c-pakeistieji-2-modifikuoti-n6- pakeistieji purino nukleotidai, skirti hcv gydymui